Evidence map›Paper›PMID 39515852›Full record

ArticleBMJ open2024

Acceptability, barriers and facilitators of using dried blood spots-point-of-care testing for sickle cell disease in Africa: an implementation science protocol for a multinational qualitative study.

Obiageli Eunice Nnodu, Nchangwi Syntia Munung, Lulu Chirande, Catherine Chunda-Liyoka, Sarah Kiguli, Fred Stephen Sarfo, Boubacari Ali Touré, Emmanuel Balandya, Aldiouma Guindo, Patience Kuona and 14 more

Abstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Obiageli Eunice NnoduCenter of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria nchangwisyntia@yahoo.com oennodu@gmail.com awonkam1@jhmi.edu ep91@nyu.edu.ORCID http://orcid.org/0000-0002-4801-3156
Nchangwi Syntia MunungDivision of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa nchangwisyntia@yahoo.com oennodu@gmail.com awonkam1@jhmi.edu ep91@nyu.edu.ORCID http://orcid.org/0000-0003-1498-3602
Lulu ChirandeDepartment of Paediatrics and Child Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Catherine Chunda-LiyokaMinistry of Health, Lusaka, Zambia.
Sarah KiguliDepartment of Paediatrics and Child Health, Makerere University Faculty of Medicine, Kampala, Uganda.
Fred Stephen SarfoNeurology Unit, Department of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.ORCID http://orcid.org/0000-0001-7274-5093
Boubacari Ali TouréCentre de Recherche et Lutte contre la Drépanocytose (CRLD), Bamako, Mali.
Emmanuel BalandyaDepartment of Physiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of.
Aldiouma GuindoCentre de Recherche et Lutte contre la Drépanocytose (CRLD), Bamako, Mali.
Patience KuonaFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Kevin EsohDivision of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Mario JonasDivision of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Maxwell NwegbuCenter of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Upendo MasamuThe Sickle Cell Programme, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of.
Jack MorriceDivision of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Patrick Ohiani MoruCenter of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Valentina Ngo BitounguiFaculty of Medicine and Pharmaceutical Science, University of Dschang, Dschang, Cameroon.
Victoria NembawareDivision of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-7966-4042
Siana NkyaThe Sickle Cell Programme, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of.
Léon TshiloloInstitut de Recherche Biomédicale, Centre Hospitalier Mère-Enfant, Université de Mbuji-Mayi, Mbuji-Mayi, Congo (the Democratic Republic of the).
Julie MakaniThe Sickle Cell Programme, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of.
Ambroise WonkamDivision of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa nchangwisyntia@yahoo.com oennodu@gmail.com awonkam1@jhmi.edu ep91@nyu.edu.
Emmanuel PeprahSchool of Global Public Health, New York University, New York, New York, USA nchangwisyntia@yahoo.com oennodu@gmail.com awonkam1@jhmi.edu ep91@nyu.edu.
SickleInAfrica Consortium

Funding

Sickle Africa Data Coordinating CenterU24HL135600 · NHLBI · UNIVERSITY OF CAPE TOWN · PI MULDER, NICOLA, WONKAM, AMBROISE · 2017 to 2025
$8.6M
The Sickle Pan-African Research Consortium (SPARCO)U24HL135881 · NHLBI · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI MAKANI, JULIE · 2017 to 2025
$5.3M
Sickle Pan-African Research Consortium (SPARCO)- TanzaniaU01HL156853 · NHLBI · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI BALANDYA, EMMANUEL · 2021 to 2025
$1.5M
Ghana-SPARCO: Ghana Sickle Pan-African Research ConsortiumU01HL157004 · NHLBI · KWAME NKRUMAH UNIVERSITY/SCIENCE/TECH · PI OFORI-ACQUAH, SOLOMON FIIFI, SARFO, FRED STEPHEN · 2021 to 2025
$1.4M
Sickle Pan African Research Consortium NigEria (SPARC-NEt)U01HL156942 · NHLBI · UNIVERSITY OF ABUJA · PI NNODU, OBIAGELI EUNICE · 2021 to 2025
$1.3M
Sickle Pan-African Research Consortium (SPARCO) Uganda: Strengthening Capacity for Clinical Care, Research and Training in Sickle Cell Disease - SCRT Project.U01HL156914 · NHLBI · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI KIGULI, SARAH · 2021 to 2025
$993k
Sickle Hemoglobinopathy reseArch in Zimbabwe (SHAZ)U01HL156943 · NHLBI · COLLEGE OF HEALTH SCIS UNIV OF ZIMBABWE · PI KUONA, PATIENCE · 2021 to 2025
$904k
Improving Sickle Cell Disease Care in Mali through Engagement with a Pan-African Sickle Cell Disease Network.U01HL157007 · NHLBI · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI GUINDO, ALDIOUMA · 2021 to 2025
$892k
NHLBI NIH HHS U01 HL156853NHLBI NIH HHS U01 HL156914NHLBI NIH HHS U01 HL156942NHLBI NIH HHS U01 HL156943NHLBI NIH HHS U01 HL157004NHLBI NIH HHS U01 HL157007NHLBI NIH HHS U24 HL135600NHLBI NIH HHS U24 HL135881
6 · The paper itself

Abstract

backgroundSickle cell disease (SCD) is a prevalent inherited blood disorder. Globally, approximately 515 000 babies are born with SCD annually, with 75% of these births occurring in Africa. Integrating newborn screening (NBS) for SCD into primary healthcare structures, such as immunisation programmes, holds significant promise, with dried blood spots (DBS)-point-of-care technologies (POCT) like HaemoTypeSC offering cost-effective screening solutions. However, scaling up DBS-POCT for NBS of SCD in Africa remains challenging.

objectiveThis study aims to explore individual, organisational and external factors that may influence the reliability, feasibility, acceptability, adoption and sustainability of using DBS-POCT with HaemoTypeSC for NBS of SCD at primary healthcare centres in African countries.

methodThis qualitative study will be conducted in seven African countries that are part of the SickleInAfrica consortium sites. The study design is informed by the Consolidated Framework for Implementation Research (CFIR) and the Implementation Outcome Model. Participants will be mothers whose babies have been diagnosed with SCD, healthcare professionals and policy-makers. In-depth interviews and focus group discussions will be used for data collection. Data analysis will be through thematic analysis. ETHICS AND DISSEMINATION: Research ethics approvals have been obtained from the seven countries. Written informed consent will be obtained from all participants. The study results will be disseminated in peer-reviewed scientific journals, scientific conferences, reports to national ministries of public health and webinars.

Indexed as

Anemia, Sickle CellImplementation ScienceNeonatal ScreeningQualitative ResearchAfricaDried Blood Spot TestingHumansInfant, NewbornPatient Acceptance of Health CarePoint-of-Care TestingResearch DesignHaematopathologyImplementation SciencePAEDIATRICSParents

Identifiers

PMID39515852
PMCPMC12004497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.